Treatment of Non-Infectious Posterior Uveitis with Dexamethasone Intravitreal Implants in a Real-World Setting

References

• Durrani OM. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159–1162. doi:10.1136/bjo.2003.037226
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49(3):438–445. doi:10.1016/j.semarthrit.2019.06.004
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi:10.1136/bjo.80.4.332
   PubMed Web of Science ®Google Scholar
• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–236. doi:10.1159/000078612
   PubMed Web of Science ®Google Scholar
• Tallouzi MO, Moore DJ, Bucknall N, et al. Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophthalmol. 2020;5(1):e000481. doi:10.1136/bmjophth-2020-000481
   PubMed Web of Science ®Google Scholar
• Naik RK, Rentz AM, Foster CS, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol. 2013;131(2):219. doi:10.1001/2013.jamaophthalmol.102
   PubMed Web of Science ®Google Scholar
• Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med. 2021;8:695904. doi:10.3389/fmed.2021.695904
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:10.1080/09273948.2016.1196713
   PubMed Web of Science ®Google Scholar
• García-Aparicio Á, García de Yébenes MJ, Otón T, Muñoz-Fernández S. Prevalence and incidence of uveitis: a systematic review and meta-analysis. Ophthalmic Epidemiol. 2021;28(6):461–468. doi:10.1080/09286586.2021.1882506
   PubMed Web of Science ®Google Scholar
• Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–1449. doi:10.1016/j.ophtha.2006.03.027
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Cassoux N, Wechsler B, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine. 2001;80(4):263–270. doi:10.1097/00005792-200107000-00005
   PubMed Web of Science ®Google Scholar
• Gritz D. Incidence and prevalence of uveitis in Northern California The Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500. doi:10.1016/j.ophtha.2003.06.014
   PubMed Web of Science ®Google Scholar
• Thorne JE, Suhler E, Skup M, et al. Prevalence of non-infectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol. 2016;134(11):1237–1245. doi:10.1001/jamaophthalmol.2016.3229
   PubMed Web of Science ®Google Scholar
• Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and uveitis. Surv Ophthalmol. 2013;58(1):1–10. doi:10.1016/j.survophthal.2012.04.006
   PubMed Web of Science ®Google Scholar
• Tan HY, Agarwal A, Lee CS, et al. Management of noninfectious posterior uveitis with intravitreal drug therapy. Clin Ophthalmol. 2016;10:1983–2020. doi:10.2147/OPTH.S89341
   PubMedGoogle Scholar
• de Smet MD, Taylor SRJ, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452–470. doi:10.1016/j.preteyeres.2011.06.005
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–848. doi:10.1136/bjo.80.9.844
   PubMed Web of Science ®Google Scholar
• Rosenbaum J, Pasadhika S. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther. 2014;67. doi:10.2147/BTT.S41477
   PubMedGoogle Scholar
• Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 2011;1613. doi:10.2147/OPTH.S17419
   PubMedGoogle Scholar
• Abdulla D, Ali Y, Menezo V, Taylor SRJ. The use of sustained release intravitreal steroid implants in non-infectious uveitis affecting the posterior segment of the eye. Ophthalmol Ther. 2022;11(2):479–487. doi:10.1007/s40123-022-00456-4
   PubMed Web of Science ®Google Scholar
• Cabrera M, Yeh S, Albini TA. Sustained-release corticosteroid options. J Ophthalmol. 2014;2014:1–5. doi:10.1155/2014/164692
   Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80–86. doi:10.1167/iovs.10-5285
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134–1146.e3. doi:10.1016/j.ophtha.2010.03.032
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Ophthalmology. 2011;118(12):2453–2460. doi:10.1016/j.ophtha.2011.05.014
   PubMed Web of Science ®Google Scholar
• Lowder C. Dexamethasone intravitreal implant for non-infectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545. doi:10.1001/archophthalmol.2010.339
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914. doi:10.1016/j.ophtha.2014.04.024
   PubMed Web of Science ®Google Scholar
• The National Institute for Health and Care Excellence (NICE). Adalimumab and dexamethasone for treating non-infectious uveitis. Available from: https://www.nice.org.uk/guidance/ta460/chapter/1-Recommendations. Accessed January 17, 2023.
   Google Scholar
• Adán A, Pelegrín L, Rey A, et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013;33(7):1435–1440. doi:10.1097/IAE.0b013e31827e247b
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Cerón OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther. 2013;29(5):501–507. doi:10.1089/jop.2012.0180
   PubMed Web of Science ®Google Scholar
• Saincher SS, Gottlieb C. Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. J Ophthalmic Inflamm Infect. 2020;10(1):1. doi:10.1186/s12348-019-0189-4
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Taylor SRJ, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121(8):1649–1654. doi:10.1016/j.ophtha.2014.02.003
   PubMed Web of Science ®Google Scholar
• Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136–1145.e5. doi:10.1016/j.ajo.2014.09.003
   PubMed Web of Science ®Google Scholar
• Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. 2009;247(1):137–142. doi:10.1007/s00417-008-0926-0
   PubMed Web of Science ®Google Scholar
• Tufail A, Lightman S, Kamal A, et al. Post-marketing surveillance study of the safety of dexamethasone intravitreal implant in patients with retinal vein occlusion or noninfectious posterior segment uveitis. Clin Ophthalmol. 2018;12:2519–2534. doi:10.2147/OPTH.S181256
   PubMed Web of Science ®Google Scholar
• Palla S, Biswas J, Nagesha C. Efficacy of Ozurdex implant in treatment of noninfectious intermediate uveitis. Indian J Ophthalmol. 2015;63(10):767. doi:10.4103/0301-4738.171505
   PubMed Web of Science ®Google Scholar
• Hasanreisoğlu M, Özdemir HB, Özkan K, et al. Intravitreal Dexamethasone Implant in the Treatment of Non-infectious Uveitis. Turk J Ophthalmol. 2019;49(5):250–257. doi:10.4274/tjo.galenos.2019.81594
   PubMedGoogle Scholar
• European Medicines Agency. Ozurdex: EPAR - product information. European Medicines Agency; 2022. Available from: https://www.ema.europa.eu/documents/product-information/ozurdex-epar-product-information_en.pdf. Accessed January 17, 2023.
   Google Scholar
• Brady CJ, Villanti AC, Law HA, et al. Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev. 2016;2:CD010469. doi:10.1002/14651858.CD010469.pub2
   PubMedGoogle Scholar
• Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and rare ocular side-effects of the dexamethasone implant. Ocul Immunol Inflamm. 2016;1–7. doi:10.1080/09273948.2016.1184284
   Web of Science ®Google Scholar
• Modugno RL, Testi I, Pavesio C. Intraocular therapy in noninfectious uveitis. J Ophthalmic Inflamm Infect. 2021;11(1):37. doi:10.1186/s12348-021-00267-x
   PubMed Web of Science ®Google Scholar
• Mikhail M, Sallam A. Novel intraocular therapy in non-infectious uveitis of the posterior segment of the eye. Med Hypothesis Discov Innov Ophthalmol J. 2013;2(4):113–120.
   PubMedGoogle Scholar
• Soheilian M, Eskandari A, Ramezani A, Rabbanikhah Z, Soheilian R. A pilot study of intravitreal diclofenac versus intravitreal triamcinolone for uveitic cystoid macular edema. Ocul Immunol Inflamm. 2013;21(2):124–129. doi:10.3109/09273948.2012.745883
   PubMed Web of Science ®Google Scholar
• Kianersi F, Rezaeian-Ramsheh A, Pourazizi M, Kianersi H. Intravitreal diclofenac for treatment of refractory uveitis-associated cystoid macular oedema: a before and after clinical study. Acta Ophthalmol. 2018;96(3):e355–e360. doi:10.1111/aos.13604
   PubMed Web of Science ®Google Scholar
• Zaki AM, Suhler EB. Biologics in non-infectious uveitis past, present and future. Ann Eye Sci. 2021;6:20. doi:10.21037/aes-20-80
   Google Scholar
• He Y, Jia SB, Zhang W, Shi JM. New options for uveitis treatment. Int J Ophthalmol. 2013;6(5):702–707. doi:10.3980/j.issn.2222-3959.2013.05.29
   PubMed Web of Science ®Google Scholar